Overview

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Treatments:
Linagliptin